-
The EMA launched a review of sartan medicines in 2018 after probable carcinogenic impurities were discovered.
-
The triglyceride-glucose index may be a valuable marker for poor COVID-19 outcomes.
-
Only a minority of patients achieve glycemic targets, receive treatment for hypertension, dyslipidemia.

Some cardiology patients may be at increased risk of contracting the virus, while COVID-19 treatments can also lead to cardiac damage.